Loading...
Publication
Novos antibiĆ³ticos antiparietais
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| PPG_25687 | 2.25 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Os antibiĆ³ticos Ī²-lactĆ¢micos, pertencentes ao grupo dos antibiĆ³ticos antiparietais sĆ£o, simultaneamente, a famĆlia mais numerosa de antibacterianos e a mais utilizada na prĆ”tica clĆnica, actuando por inibiĆ§Ć£o da Ćŗltima etapa da sĆntese da parede celular bacteriana, nomeadamente na fase parietal da biossĆntese do peptidoglicano. ApĆ³s a descoberta da penicilina, em 1928, verificou-se um desenvolvimento exponencial de novos compostos capazes de combater as doenƧas infecciosas que se revelavam, nĆ£o raras vezes, fatais. Contudo, este desenvolvimento foi acompanhado pelo surgimento, a um ritmo ainda mais acelerado, de novos mecanismos de resistĆŖncia por parte das bactĆ©rias que representam, actualmente, um elevado foco de apreensĆ£o temendo-se, a curto prazo, um cenĆ”rio de inexistĆŖncia de molĆ©culas eficazes no combate a infecƧƵes, mesmo aquelas consideradas relativamente corriqueiras e triviais.
Ao longo desta monografia pretende-se apurar o actual panorama do armamento terapĆŖutico no que diz respeito Ć sua eficĆ”cia, ao flagelo das resistĆŖncias e Ć s potenciais soluƧƵes alternativas com novos compostos que se revelam promissores.
Ī²-lactam antibiotics, which belong to the group of antiparietal antibiotics are, simultaneously, the largest family of antibacterial agents and the most widely used in clinical practice, acting by inhibition of the last step of bacterial cell wall synthesis, particularly in the parietal phase of peptidoglycan biosynthesis. After the discovery of penicillin, in 1928, there was an exponential development of new compounds capable of fighting infectious diseases that were usually fatal. However, this development was followed by the emergence, at an even faster pace, of new resistance mechanisms by bacteria, representing a high level of apprehension and, in the short term, fears of a lack of effective molecules in the fight against infections, even those considered relatively commonplace and trivial. Throughout this monograph it is intended to investigate the current panorama of therapeutic armaments with regard to their effectiveness, the scourge of resistances and the potential alternative solutions with new compounds that are proving promising.
Ī²-lactam antibiotics, which belong to the group of antiparietal antibiotics are, simultaneously, the largest family of antibacterial agents and the most widely used in clinical practice, acting by inhibition of the last step of bacterial cell wall synthesis, particularly in the parietal phase of peptidoglycan biosynthesis. After the discovery of penicillin, in 1928, there was an exponential development of new compounds capable of fighting infectious diseases that were usually fatal. However, this development was followed by the emergence, at an even faster pace, of new resistance mechanisms by bacteria, representing a high level of apprehension and, in the short term, fears of a lack of effective molecules in the fight against infections, even those considered relatively commonplace and trivial. Throughout this monograph it is intended to investigate the current panorama of therapeutic armaments with regard to their effectiveness, the scourge of resistances and the potential alternative solutions with new compounds that are proving promising.
Description
Keywords
AntibiĆ³ticos Antiparietais Ī²-lactĆ¢micos ResistĆŖncia Ī²-lactamases Peptidoglicano Antibiotics Antiparietal Ī²-lactams Resistance Ī²-lactamases Peptidoglycan